Bristol-Myers Squibb Co vs Flagstar Bank NA — how do they compare? Bristol-Myers Squibb Co trades at $63.97 (market cap $129.94B), while Flagstar Bank NA trades at $14.26 (market cap $5.89B). The key difference: Bristol-Myers Squibb Co is far larger — about 22.1× Flagstar Bank NA's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | FLG | |
|---|---|---|
Market Cap | $129.94B | $5.89B |
Sector | Health | Financials |
52-Week High | $65.89 | $15.36 |
52-Week Low | $42.60 | $10.72 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 0.28% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Flagstar Bank (FLG) trades at $14.285, up 1.96% today, with a bullish technical signal from moving averages and a consensus analyst price target of $16.85. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and dividend payments reflect strong capital management, while proprietary technology initiatives aim to bolster long-term growth.
The outlook is cautiously optimistic, with potential upside from execution on strategic initiatives and valuation support from a low P/B ratio of 0.77. Risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. Analyst sentiment is positive with no sell ratings, but investors should monitor fee income trends and credit quality.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →